Related references
Note: Only part of the references are listed.Simultaneous determination of tenofovir alafenamide and tenofovir in human plasma by LC-MS/MS and its application to pharmacokinetics study in clinic
Lizhi Zhao et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2019)
Development and validation of an LC-MS/MS assay for tenofovir and tenofovir alafenamide in human plasma and cerebrospinal fluid
Andrew J. Ocque et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2018)
Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection
Emma D. Deeks
DRUGS (2018)
Intracellular Activation of Tenofovir Alafenamide and the Effect of Viral and Host Protease Inhibitors
Gabriel Birkus et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection
Sarah L. Greig et al.
DRUGS (2016)
Implications of Efficient Hepatic Delivery by Tenofovir Alafenamide (GS-7340) for Hepatitis B Virus Therapy
Eisuke Murakami et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection
Kosh Agarwal et al.
JOURNAL OF HEPATOLOGY (2015)
Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity
Rujuta A. Bam et al.
ANTIVIRAL THERAPY (2014)
Tenofovir-associated renal and bone toxicity
C. L. N. Woodward et al.
HIV MEDICINE (2009)
Share Paper
